Jon Hoggard
Posted by

Patient information at Leukaemia & Lymphoma Research

Jon Hoggard
Posted by
02 Sep 2014

Read more about how our patient information is produced, from our extensive re-writes and redesigns to our robust clinical and lay review process.

We’re currently doing an important piece of work to revamp the patient information materials we offer to people affected by blood cancer – everything from printed booklets and videos to the information we make available online. Thousands of people use our patient information every year, so we want to make sure it’s absolutely the best it can be.

A key part of this revamp is to develop our new production process and review procedures. These will be robust, calling on the expertise and experiences of leading health professionals, patients and their families, to provide insight and help guide and support the production of our patient information.

These new procedures are in line with the Information Standard scheme – a certification programme run by NHS England which ensures any information produced is balanced, evidence-based, regularly reviewed and tested by its users.

Another part of our revamp is looking at the designs of our information materials, to make sure our revised content is presented in a way that works for patients and that stands out from the crowd. To help with this we’ve sought feedback from patients, clinicians and nurse specialists to find out their likes and dislikes, and what’s important for them when viewing patient information.

We will never stop looking to improve our patient information and welcome any feedback. We will regularly put our information through a rigorous process of review using patients and clinicians in order to make sure it’s as accurate, up to date and supportive as possible, and will look to fill any information gaps currently experienced by people affected by blood cancer.

Information review process

1. We start each review by assessing the current version, highlighting any issues or sections we know need updating. At this stage we also review any feedback received since the previous revision.

2. We then hold a review meeting with a clinical member of our Medical Advisory Panel (MAP), who checks the current version and recommends any alterations or updates, and uses current evidence sources to provide these as necessary. All sources of evidence are checked and recorded, to be available if requested.

3. These amendments are then collated and the draft is prepared to be rewritten by our in-house team. Once rewritten, the new draft is sent out for review by patients and health professionals, including the original MAP member.

4. Any comments or alterations from these reviews are collated and made to the draft, before the draft is sent to our in-house design team. Once designed, this is proofread and again sent out for a final review by patients, health professionals, and any relevant patient organisations. The final designed version is signed off by the MAP member.

5. We continue to seek feedback on the new title once released, which we can then feed back into the next revision.



I currently attended an afternoon tea with the Lymphoma Group after having taken part in a video experience during the past four years of my treatment for Non Hodgkin Mantel Cell Lymphoma, I found the support given by the group very uplifting and would recommend supporting their work.The picture was taken at the event a is of my wife and Victoria


Hi Brian, thanks very much for your message, it was lovely to meet you and your wife at the afternoon tea. We hope you enjoyed it! Thanks again for all you've done for Leukaemia & Lymphoma Research, and do please keep in touch. 

Best wishes for the New Year,